Financial PerformanceAdjusted EPS for TCMD came in above estimates, reflecting stronger profitability than anticipated.
Operational EfficiencyAR is coming down from faster Medicare collections, OMs are expanding, and cash-flow generation is tracking ahead of LT targets.
Product DevelopmentTCMD's Airway Clearance is expected to return to growth, and a new Lymphedema system is anticipated later in FY24.